Results 101 to 110 of about 28,272 (264)

Potential of PCSK9 as a new target for the management of LDL cholesterol

Research Reports in Clinical Cardiology, 2015
Guiliana Mombelli, Samuela Castelnuovo, Chiara PavanelloCardiovascular Department, Dyslipidemia Center, Azienda Ospedaliera Niguarda Cà Granda, Milan, ItalyAbstract: A large proportion of patients at high risk for cardiovascular disease continue ...
Mombelli G, Castelnuovo S, Pavanello C
doaj  

Biosynthesis and enzymology of the Caenorhabditis elegans cuticle: identification and characterization of a novel serine protease inhibitor. [PDF]

, 2006
The nematode Caenorhabditis elegans represents an excellent model in which to examine nematode gene expression and function. A completed genome, straightforward transgenesis, available mutants and practical genome-wide RNAi approaches provide an ...
Andrew J. Birnie, Antony P. Page, Brenner, Brooks, Canty, Chu, Davis, Edens, Eschenlauer, Frand, Friedman, Gillian McCormack, Hawdon, Hill, Johnstone, Kamath, Kamath, Kramerova, Kramerova, Kress, Lustigman, Milstone, Myllyharju, Myllyharju, Novelli, Page, Page, Page, Page, Page, Pappano, Peters, Poole, Roberts, Sapio, Simmer, Singh, Sulston, Thacker, Thacker, Thein, Winter, Yang   +42 more
core   +1 more source

Hepatic GCGR is required for the superior weight loss and metabolic effects of a structurally related analogue of the dual GCGR/GLP‐1R agonist survodutide in mice

Diabetes, Obesity and Metabolism, EarlyView.
Fen Long, Tenagne D. Challa, Vissarion Efthymiou, Manuel Klug, Thomas Klein, Heike Neubauer, Christian Wolfrum, Carla Horvath   +7 more
wiley   +1 more source

Rationale and Design of the PASSIVATE‐CAP Trial: The Preventive Intervention Value of Drug‐Coated Balloons in Vulnerable Coronary Atherosclerotic Plaques

Clinical Cardiology, Volume 49, Issue 1, January 2026.
PASSIVATE‐CAP Research Overview and Flowchart. ABSTRACT Background Patients with acute coronary syndrome (ACS) face a significantly increased risk of cardiovascular events due to vulnerable plaques. However, no clear evidence supports performing preventive percutaneous coronary intervention (PCI) for non‐flow‐limiting vulnerable plaques.
Zhongxiu Chen, Junyan Zhang, Minggang Zhou, Shichu Liang, Yong Chen, Chen Li, Hua Wang, Jiafu Wei, Baotao Huang, Mian Wang, Yong He, for the PASSIVATE‐CAP trial investigator   +11 more
wiley   +1 more source

Hepatocellular carcinoma-associated hypercholesterolemia: involvement of proprotein-convertase-subtilisin-kexin type-9 (PCSK9)

Cancer & Metabolism, 2018
Background PCSK9 regulates low-density lipoprotein cholesterol (LDLc) level and has been implicated in hypercholesterolemia. Aberrant plasma lipid profile is often associated with various cancers.
Dipti Athavale, Surbhi Chouhan, Vimal Pandey, Shyamananda Singh Mayengbam, Snahlata Singh, Manoj Kumar Bhat   +5 more
doaj   +1 more source

Functional Amyloid Formation within Mammalian Tissue [PDF]

, 2005
Amyloid is a generally insoluble, fibrous cross-β sheet protein aggregate. The process of amyloidogenesis is associated with a variety of neurodegenerative diseases including Alzheimer, Parkinson, and Huntington disease.
Atanas V Koulov, Baxa, Berson, Berson, Caughey, Chakraborty, Chapman, Chen, Chen, Chiti, Christelle Alory-Jost, Cohen, Dobson, Douglas M Fowler, Eanes, Fink, Hearing, Hoashi, Jeffery W Kelly, Johnson, Jonathan Weissman, Kelly, Kenney, Kerje, Klunk, Klunk, Krebs, Land, Lashuel, Lashuel, Lee, Linke, Marks, Michael S Marks, Pawelek, Petkova, Provencher, Quevedo, Raposo, Schonthaler, Scott, Sekijima, Shorter, Si, Silvers, Singh, Spanakis, Sreerama, Tanaka, Westermark, William E Balch   +50 more
core   +4 more sources

Optimization of 4‐Amino‐2‐Pyridone Inhibitors of Proprotein Convertase Subtilisin/Kexin Type 9: Integrating Structure–Activity and Structure–Metabolism Relationships

ChemMedChem, Volume 21, Issue 1, January 2026.
Green chemistry‐based late‐stage functionalization (LSF) of the anti‐proprotein convertase subtilisin/kexin type 9 (PCSK9) early lead compound 5c led to optimized analogs with improved metabolic stability/PCSK9 IC50 ratio. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key drug target for the treatment of different hypercholesterolemia ...
Lisa Giannessi, Maria Giovanna Lupo, Martina Ugolotti, Bianca Papotti, Beatrice Mattina, Maria Grazia Martina, Anna Demurtas, Cristina Padula, Sara Nicoli, Marco Crescenzio, Nicola Ferri, Francesca Zimetti, Marco Radi   +12 more
wiley   +1 more source

Assessment of serum proprotein convertase subtilisin/kexin type 9 in pediatric sepsis syndrome

Scientific Reports
Sepsis is a life-threatening condition that arises when the body's response to infection causes injury to its tissues and organs. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme released in response to the drop in cholesterol level ...
Suzan Omar Mousa, Mohamed Farouk Afifi, Noha Anwar Hassuna, Michael Fekry Yassa, Hend Mohamed Moness   +4 more
doaj   +1 more source

Low-density lipoprotein cholesterol lowering therapies: what is on the horizon? [PDF]

, 2015
Elevated low-density lipoprotein cholesterol (LDL-C) levels are associated with an increased risk for cardiovascular disease (CVD). Statins have been the cornerstone of lipid therapy to lower LDL-C for the past two decades, but despite significant ...
Figueredo, M.D., Vincent M, Gadi, Ramprasad   +1 more
core   +1 more source

Transport and equilibrium uptake of a peptide inhibitor of PACE4 into articular cartilage is dominated by electrostatic interactions [PDF]

, 2010
The availability of therapeutic molecules to targets within cartilage depends on transport through the avascular matrix. We studied equilibrium partitioning and non-equilibrium transport into cartilage of Pf-pep, a 760 Da positively charged peptide ...
Byun, Sangwon, Fok, Kam, Frank, Eliot, Grodzinsky, Alan J., Malfait, Anne-Marie, Tortorella, Micky D.   +5 more
core   +1 more source